Streptococcus agalactiae highly resistant to fluoroquinolones

被引：13

作者：

Miro, Elisenda

Rebollo, Montserrat

Rivera, Alba

Alvarez, M. Teresa

Navarro, Ferran

Mirelis, Beatriz

Coll, Pere

机构：

[1] Hosp Santa Creu & Sant Pau, Microbiol Serv, Barcelona, Spain

[2] Hosp Santa Creu & Sant Pau, Unidad Enfermedades Infecciosas, Barcelona, Spain

[3] Univ Autonoma Barcelona, Dept Genet & Microbiol, Unidad Microbiol, E-08193 Barcelona, Spain

来源：

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2006年 / 24卷 / 09期

关键词：

Streptococcus agalactiae; fluoroquinolones; parC; gyrA;

D O I：

10.1157/13093876

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

BACKGROUND. Streptococcus agalactiae remains susceptible to penicillin; nevertheless, an increase in the resistance to other antimicrobial families, such as macrolides and more rarely fluoroquinolones, has been described. METHODS AND RESULTS. From 2003 to 2004, two fluoroquinolone-resistant S. agalactiae strains were detected. The strains presented one mutation in parC (Ser(79) -> Phe) and an additional mutation in gyrA (Glu(85) -> Ala or Glu(85) -> Lys). CONCLUSION. This study describes the first S. agalactiae strains highly resistant to fluoroquinolones in Spain.

引用

收藏

页码：562 / 563

页数：2

相关论文

共 10 条

[1] Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000) [J].

Davies, TA ;

Goldschmidt, R ;

Pfleger, S ;

Loeloff, M ;

Bush, K ;

Sahm, DF ;

Evangelista, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (02) :168-175

[2] Multicenter study of the mechanisms of resistance and clonal relationships of Streptococcus agalactiae isolates resistant to macrolides, lincosamides, and ketolides in Spain [J].

Gonzalez, JJ ;

Andreu, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2525-2527

[3] Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season [J].

Jones, ME ;

Sahm, DF ;

Martin, N ;

Scheuring, S ;

Heisig, P ;

Thornsberry, C ;

Köhrer, K ;

Schmitz, FJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :462-466

[4] First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC [J].

Kawamura, Y ;

Fujiwara, H ;

Mishima, N ;

Tanaka, Y ;

Tanimoto, A ;

Ilawa, S ;

Itoh, Y ;

Ezaki, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3605-3609

[5]

Liñares J, 1999, NEW ENGL J MED, V341, P1546

[6] Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes [J].

Malhotra-Kumar, S ;

Lammens, C ;

Chapelle, S ;

Mallentjer, C ;

Weyler, J ;

Goossens, H .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (03) :320-325

[7]

NCCLS-National Committee for Clinical Laboratory Standards, 2003, PERF STAND ANT DISK

[8] The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations [J].

Richter, SS ;

Heilmann, KP ;

Beekmann, SE ;

Miller, NJ ;

Rice, CL ;

Doern, GV .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (02) :225-235

[9] Epidemiology of group B streptococcal disease in the United States: Shifting paradigms [J].

Schuchat, A .

CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (03) :497-+

[10] Fluoroquinolone-resistant Streptococcus agalactiae:: Epidemiology and mechanism of resistance [J].

Wehbeh, W ;

Rojas-Diaz, R ;

Li, XY ;

Mariano, N ;

Grenner, L ;

Segal-Maurer, S ;

Tommasulo, B ;

Drlica, K ;

Urban, C ;

Rahal, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2495-2497